Stock Analysis
- Sweden
- /
- Medical Equipment
- /
- OM:EKTA B
Elekta First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Elekta (STO:EKTA B) First Quarter 2025 Results
Key Financial Results
- Revenue: kr3.83b (flat on 1Q 2024).
- Net income: kr70.0m (down 71% from 1Q 2024).
- Profit margin: 1.8% (down from 6.2% in 1Q 2024).
- EPS: kr0.18 (down from kr0.62 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Elekta Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 4.5%. Earnings per share (EPS) missed analyst estimates by 38%.
Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 2.8% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Elekta that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Elekta might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:EKTA B
Elekta
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide.